undamentalytics Newsletter
Sign in

Xilio Therapeutics, Inc. income statement

In fiscal 2025, Xilio Therapeutics, Inc. reported revenue of $43.8m, up 589.9% on the year before, operating income of −$42.0m (a -95.9% margin) and net income of −$35.0m, or −$4.19 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2024Dec 20242025Dec 2025LTMJun 2026
Revenue64464
Research and development415667
General and administrative253029
Operating income−61−42−31
Income before tax−58−35—
Income tax00—
Net income−58−35−22
Diluted EPS−$15.24−$4.19—
Diluted shares (average)4m8m—
EBITDA−59−40−30

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CUVL vs XLOABCL vs XLOCYTK vs XLO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Xilio Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Xilio Therapeutics, Inc.